TY - JOUR
T1 - Prospectively randomized north central cancer treatment group trial of intensive-course fluorouracil combined with the l-isomer of intravenous leucovorin, oral leucovorin, or intravenous leucovorin for the treatment of advanced colorectal cancer
AU - Goldberg, Richard M.
AU - Hatfield, Alan K.
AU - Kahn, Michael
AU - Sargent, Daniel J.
AU - Knost, James A.
AU - O'Connell, Michael J.
AU - Krook, James E.
AU - Mailliard, James A.
AU - Wiesenfeld, Martin
AU - Schaefer, Paul L.
AU - Tirona, Maria Tria
AU - Moertel, Charles G.
PY - 1997/11
Y1 - 1997/11
N2 - Purpose: A three-arm randomized phase III trial in advanced colorectal cancer patients was designed to test whether substitution of an equivalent dose of (1) l-leucovorin or (2) oral leucovorin would more effectively potentiate fluorouracil (5-FU) than standard intravenous (IV) (d,l)- leucovorin. Patients and Methods: A total of 926 chemotherapy-naive patients participated. Patients received one of three treatments: (A) intensive- course 5-FU plus/-leucovorin with IV leucovorin (Immunex Corp, Seattle, WA) at 100 mg/m2 and IV 5-FU at 370 mg/m2; (B) intensive-course 5-FU plus oral (d,I)-leucovorin with oral leucovorin at 125 mg/m2 on hours 0, 1, 2, and 3 (total dose, 500 mg/m2) followed by 5-FU 370 mg/m2 on hour 4; or (C) intensive-course 5-FU plus IV (d,I)-leucovorin with IV leucovorin 200 mg/m2 and 5-FU 370 mg/m2. Drugs were administered daily for 5 consecutive days. Courses were repeated at 4 and 8 weeks, and every 5 weeks thereafter. Dosage was reduced for neutropenia, thrombocytopenia, diarrhea, stomatitis, and dermatitis. Results: Of 926 eligible patients, 756 have died. The overall response rate for patients with measurable disease was 32% (165 of 514). There were no differences between regimens in response rates (arm A, 28% [47 of 140]; arm B, 34% [60 of 174]; and arm C, 34% [58 of 170]) or in survival. There have been nine possible chemotherapy-related fatalities. Grade III to IV toxic effects did not differ appreciably by arm and included stomatitis (12% to 14%), diarrhea (15% to 19%), nausea (7% to 9%), and vomiting (6% to 8%). Conclusion: There was no difference in response, survival, or toxicity between these three different leucovorin formulations combined with 5-FU.
AB - Purpose: A three-arm randomized phase III trial in advanced colorectal cancer patients was designed to test whether substitution of an equivalent dose of (1) l-leucovorin or (2) oral leucovorin would more effectively potentiate fluorouracil (5-FU) than standard intravenous (IV) (d,l)- leucovorin. Patients and Methods: A total of 926 chemotherapy-naive patients participated. Patients received one of three treatments: (A) intensive- course 5-FU plus/-leucovorin with IV leucovorin (Immunex Corp, Seattle, WA) at 100 mg/m2 and IV 5-FU at 370 mg/m2; (B) intensive-course 5-FU plus oral (d,I)-leucovorin with oral leucovorin at 125 mg/m2 on hours 0, 1, 2, and 3 (total dose, 500 mg/m2) followed by 5-FU 370 mg/m2 on hour 4; or (C) intensive-course 5-FU plus IV (d,I)-leucovorin with IV leucovorin 200 mg/m2 and 5-FU 370 mg/m2. Drugs were administered daily for 5 consecutive days. Courses were repeated at 4 and 8 weeks, and every 5 weeks thereafter. Dosage was reduced for neutropenia, thrombocytopenia, diarrhea, stomatitis, and dermatitis. Results: Of 926 eligible patients, 756 have died. The overall response rate for patients with measurable disease was 32% (165 of 514). There were no differences between regimens in response rates (arm A, 28% [47 of 140]; arm B, 34% [60 of 174]; and arm C, 34% [58 of 170]) or in survival. There have been nine possible chemotherapy-related fatalities. Grade III to IV toxic effects did not differ appreciably by arm and included stomatitis (12% to 14%), diarrhea (15% to 19%), nausea (7% to 9%), and vomiting (6% to 8%). Conclusion: There was no difference in response, survival, or toxicity between these three different leucovorin formulations combined with 5-FU.
UR - http://www.scopus.com/inward/record.url?scp=0030661574&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030661574&partnerID=8YFLogxK
U2 - 10.1200/JCO.1997.15.11.3320
DO - 10.1200/JCO.1997.15.11.3320
M3 - Article
C2 - 9363861
AN - SCOPUS:0030661574
SN - 0732-183X
VL - 15
SP - 3320
EP - 3329
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 11
ER -